Latisse Review: The Clinical Gold Standard
Latisse is in a category of its own. As the only FDA-approved treatment for hypotrichosis (inadequate eyelash growth), it has undergone rigorous clinical trials that no over-the-counter serum can match. Its active ingredient, bimatoprost 0.03%, was originally used as a glaucoma medication — lash growth was an observed side effect that Allergan (now AbbVie) developed into a dedicated cosmetic treatment.
Clinical Results
In FDA trials, Latisse increased lash length by 25%, thickness by 106%, and darkness by 18% versus placebo over 16 weeks. These are the largest clinically documented improvements of any lash treatment.
Important Side Effects
Latisse carries FDA-mandated warnings for potential side effects including: iris pigmentation changes (permanent darkening of eye colour in susceptible individuals), periorbital skin darkening, and eyelid skin changes. These risks underscore the importance of physician supervision.